What's Happening?
Median Technologies is set to showcase its AI/ML-based software, eyonis® LCS, at the European Congress of Radiology 2026. The software, designed for lung cancer screening, recently received FDA 510(k) clearance in the U.S. and is awaiting CE marking in Europe.
eyonis® LCS is a Software as a Medical Device (SaMD) that aids in the detection and characterization of lung cancer in low-dose CT scans, boasting high sensitivity and specificity. The company plans to demonstrate the software's clinical impact and its potential to enhance lung cancer screening programs.
Why It's Important?
The introduction of eyonis® LCS represents a significant advancement in lung cancer screening, potentially improving early detection rates and patient outcomes. By leveraging AI technology, the software aims to provide more consistent and efficient screening processes, which could lead to earlier diagnosis and treatment of lung cancer. This development is crucial as it aligns with global efforts to improve cancer detection and reduce mortality rates. The software's approval and anticipated rollout in Europe could further solidify AI's role in modern healthcare.
What's Next?
With the CE marking decision expected in Q2 2026, Median Technologies is preparing for the commercial rollout of eyonis® LCS across Europe. The company will continue to engage with the medical community at events like the European Congress of Radiology to demonstrate the software's capabilities. As the software becomes more widely adopted, it may prompt further integration of AI technologies in medical diagnostics, potentially influencing regulatory standards and healthcare practices globally.
